Corbus Current Ratio from 2010 to 2024

CRBP Stock  USD 37.70  1.54  3.92%   
Corbus Pharmaceuticals Current Ratio yearly trend continues to be relatively stable with very little volatility. Current Ratio is likely to drop to 0.70. Current Ratio is a liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities. View All Fundamentals
 
Current Ratio  
First Reported
2010-12-31
Previous Quarter
0.73825723
Current Value
0.7
Quarterly Volatility
2.82187477
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Corbus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Corbus main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Interest Expense of 2.8 M or Selling General Administrative of 14.6 B, as well as many exotic indicators such as Price To Sales Ratio of 93.82, Dividend Yield of 0.0 or Days Sales Outstanding of 191. Corbus financial statements analysis is a perfect complement when working with Corbus Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement Corbus Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Corbus Pharmaceuticals Technical models . Check out the analysis of Corbus Pharmaceuticals Correlation against competitors.

Latest Corbus Pharmaceuticals' Current Ratio Growth Pattern

Below is the plot of the Current Ratio of Corbus Pharmaceuticals Holding over the last few years. It is a liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities. Corbus Pharmaceuticals' Current Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Corbus Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 3.86 X10 Years Trend
Pretty Stable
   Current Ratio   
       Timeline  

Corbus Current Ratio Regression Statistics

Arithmetic Mean2.85
Geometric Mean1.69
Coefficient Of Variation99.14
Mean Deviation2.24
Median1.96
Standard Deviation2.82
Sample Variance7.96
Range8.381
R-Value0.14
Mean Square Error8.42
R-Squared0.02
Significance0.63
Slope0.09
Total Sum of Squares111.48

Corbus Current Ratio History

2024 0.7
2023 0.74
2022 4.76
2021 5.89
2020 2.89
2019 1.09
2018 2.45

About Corbus Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Corbus Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Corbus Pharmaceuticals investors use historical funamental indicators, such as Corbus Pharmaceuticals's Current Ratio, to determine how well the company is positioned to perform in the future. Although Corbus Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Corbus Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Corbus Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Corbus Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Corbus Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Ratio 0.74  0.70 
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Corbus Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Corbus Pharmaceuticals' short interest history, or implied volatility extrapolated from Corbus Pharmaceuticals options trading.

Pair Trading with Corbus Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Corbus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corbus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Corbus Stock

  0.67EVO Evotec SE ADR Earnings Call TomorrowPairCorr
  0.58PCRX Pacira Pharmaceuticals Financial Report 1st of May 2024 PairCorr
  0.42MGTX MeiraGTx Holdings PLC Financial Report 9th of May 2024 PairCorr
The ability to find closely correlated positions to Corbus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Corbus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Corbus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Corbus Pharmaceuticals Holding to buy it.
The correlation of Corbus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Corbus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Corbus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Corbus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Corbus Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Corbus Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Corbus Pharmaceuticals Holding Stock. Highlighted below are key reports to facilitate an investment decision about Corbus Pharmaceuticals Holding Stock:
Check out the analysis of Corbus Pharmaceuticals Correlation against competitors.
Note that the Corbus Pharmaceuticals information on this page should be used as a complementary analysis to other Corbus Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for Corbus Stock analysis

When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Is Corbus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corbus Pharmaceuticals. If investors know Corbus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corbus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(10.31)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.60)
Return On Equity
(3.42)
The market value of Corbus Pharmaceuticals is measured differently than its book value, which is the value of Corbus that is recorded on the company's balance sheet. Investors also form their own opinion of Corbus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Corbus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corbus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Corbus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Corbus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Corbus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corbus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.